Verity & Verity, LLC Gilead Sciences, Inc. Transaction History

Verity & Verity, LLC

$1.02 Billion
Q3 2024

A detailed history of Verity & Verity, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Verity & Verity, LLC holds 367,331 shares of GILD stock, worth $34.5 Million. This represents 3.02% of its overall portfolio holdings.

Number of Shares

367,331

Previous 345,695 6.26%

Holding current value

$34.5 Million

Previous $23.7 Million 29.81%

% of portfolio

3.02%

Previous 2.71%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$66.59 - $83.99 $1.44 Million - $1.82 Million	21,636 Added 6.26%	367,331 $30.8 Million
Q2 2024 Nov 07, 2024	SELL	$63.15 - $72.88 $142,087 - $163,980	-2,250 Reduced 0.61%	365,081 $25 Million
Q2 2024 Sep 16, 2024	SELL	$63.15 - $72.88 $734,181 - $847,302	-11,626 Reduced 3.25%	345,695 $23.7 Million
Q2 2024 Aug 08, 2024	BUY	$63.15 - $72.88 $17.8 Million - $20.5 Million	281,242 Added 369.67%	357,321 $24.5 Million
Q1 2024 Nov 07, 2024	SELL	$71.58 - $87.29 $2.76 Million - $3.36 Million	-38,513 Reduced 10.48%	328,818 $24.1 Million
Q1 2024 Sep 16, 2024	SELL	$71.58 - $87.29 $3.3 Million - $4.02 Million	-46,108 Reduced 12.9%	311,213 $22.8 Million
Q1 2024 Apr 24, 2024	SELL	$71.58 - $87.29 $18.6 Million - $22.6 Million	-259,342 Reduced 77.32%	76,079 $5.57 Million
Q4 2023 Nov 07, 2024	BUY	$73.27 - $83.09 $90,781 - $102,948	1,239 Added 0.36%	342,546 $27.7 Million
Q4 2023 Feb 12, 2024	BUY	$73.27 - $83.09 $169,400 - $192,104	2,312 Added 0.69%	335,421 $27.2 Million
Q3 2023 Nov 07, 2024	SELL	$73.94 - $80.67 $1.92 Million - $2.1 Million	-26,024 Reduced 7.08%	341,307 $25.6 Million
Q3 2023 Oct 19, 2023	BUY	$73.94 - $80.67 $200,229 - $218,454	2,708 Added 0.82%	333,109 $25 Million
Q2 2023 Nov 07, 2024	SELL	$76.01 - $86.7 $2.29 Million - $2.61 Million	-30,155 Reduced 8.21%	337,176 $26 Million
Q2 2023 Jul 10, 2023	BUY	$76.01 - $86.7 $1.32 Million - $1.5 Million	17,353 Added 5.54%	330,401 $25.5 Million
Q1 2023 Nov 07, 2024	SELL	$77.31 - $88.08 $3.68 Million - $4.19 Million	-47,608 Reduced 12.96%	319,723 $26.5 Million
Q1 2023 May 02, 2024	BUY	$77.31 - $88.08 $18.3 Million - $20.9 Million	236,969 Added 311.48%	313,048 $26 Million
Q1 2023 Apr 03, 2023	SELL	$77.31 - $88.08 $229,533 - $261,509	-2,969 Reduced 0.94%	313,048 $26 Million
Q4 2022 Jan 11, 2023	SELL	$62.32 - $89.47 $223,105 - $320,302	-3,580 Reduced 1.12%	316,017 $0
Q3 2022 Oct 24, 2022	BUY	$59.54 - $68.01 $592,958 - $677,311	9,959 Added 3.22%	319,597 $19.7 Million
Q2 2022 Jun 30, 2022	SELL	$57.72 - $65.01 $173,333 - $195,225	-3,003 Reduced 0.96%	309,638 $19.1 Million
Q1 2022 May 03, 2022	BUY	$57.92 - $72.58 $5.95 Million - $7.45 Million	102,665 Added 48.89%	312,641 $18.6 Million
Q4 2021 Feb 01, 2022	BUY	$64.88 - $73.64 $327,838 - $372,102	5,053 Added 2.47%	209,976 $15.2 Million
Q3 2021 Nov 04, 2021	BUY	$67.69 - $73.03 $611,376 - $659,606	9,032 Added 4.61%	204,923 $13.8 Million
Q1 2021 Jun 21, 2021	BUY	$60.0 - $68.46 $2.61 Million - $2.97 Million	43,431 Added 28.49%	195,891 $13 Million
Q4 2020 Jan 12, 2021	BUY	$56.65 - $64.55 $1.1 Million - $1.26 Million	19,497 Added 14.66%	152,460 $9.53 Million
Q3 2020 Oct 06, 2020	BUY	$62.1 - $78.08 $2.37 Million - $2.98 Million	38,200 Added 40.31%	132,963 $8.46 Million
Q2 2020 Jul 14, 2020	BUY	$72.34 - $84.0 $144,101 - $167,328	1,992 Added 2.15%	94,763 $7.27 Million
Q1 2020 Apr 09, 2020	BUY	$62.63 - $80.22 $2.03 Million - $2.61 Million	32,490 Added 53.9%	92,771 $6.94 Million
Q4 2019 Jan 08, 2020	BUY	$61.62 - $67.78 $2.2 Million - $2.42 Million	35,721 Added 145.44%	60,281 $3.92 Million
Q3 2019 Oct 11, 2019	BUY	$62.51 - $69.0 $1.54 Million - $1.69 Million	24,560 New	24,560 $1.52 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verity & Verity, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verity & Verity, LLC with notifications on news.

Account

Verity & Verity, LLC Gilead Sciences, Inc. Transaction History